(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 September 2004 (02.09.2004)

PCT

(10) International Publication Number
WO 2004/074291 A1

(51) International Patent Classification[7]: C07D 487/04, A61K 31/55, 31/501, 31/4427, A61P 29/00, C07D 498/04, 401/04, 413/14, 498/04, 513/04, 487/04, 249/00, 243/00, 498/04, 267/00, 249/00, 487/04

(21) International Application Number:
PCT/IB2004/000432

(22) International Filing Date: 9 February 2004 (09.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0303852.8 19 February 2003 (19.02.2003) GB
0317227.7 23 July 2003 (23.07.2003) GB

(71) Applicant *(for GB only)*: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB).

(71) Applicant *(for all designated States except GB)*: **PFIZER INC.** [GB/GB]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRYANS, Justin, Stephen** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB). **JOHNSON, Patrick, Stephen** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **RYCKMANS, Thomas** [BE/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB). **STOBIE, Alan** [GB/GB]; Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ (GB).

(74) Agents: **LUMB, J., Trevor** et al.; C/o Wood, David, J., Pfizer Global Research And Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRIAZOLE COMPOUNDS USEFUL IN THERAPY



(I)

(57) Abstract: A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein V represents $-(CH_2)_d(O)_e-$, -CO-, or $-CH(C_{1-6}$ alkyl)-; W is -0-, $-S(O)_a$, or $-N(R^{1'})-R^1$ represents H, C_{1-6} alkyl, $(CH_2)_bCOR^2$, $CO(CH_2)_bNR^2R^3$, $S0_2R^2$, $(^{CH}{}_2)_cOR^2$, $(CH_2)_c,NR^2R^3$, or $(CH_2)_bhet^1$; het^1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C_{1-6} alkyl; X and Y independently represent H, C_{1-6} alkyl, halogen, OH, CF_3, OCF_3, OR^4; Z represents $-(CH_2)_f(O)_g$, -CO- or $-CH(C_{1-6}$ alkyl)-; Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, $CONH_2$, CF_3, OCF3, and in which optionally at least one ring N is substituted with O; R^2 and R^3 independently represent H, C_{1-6} alkyl [optionally substituted with OH, halogen,$N(C_{1.6}$ alkyl$)_2$, or $C_{1.6}$ alkyloxy], $C_{1.6}$ alkyloxy, $N(C_{1-6}$ alkyl$)_2$, or [C_{3-8} cycloalkyl]; or R^2 and R^3, together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C_{1-6} alkyl;R4 represents straight or branched C_{1-6} alkyl, a and c independently represent 0, 1, or 2; b, e and g independently represent 0 or 1; d and f independently represent 1 or 2;are useful in the treatment of dysmenorrhoea.

WO 2004/074291 A1